Get the Stockscreener App
21.57
3.86%
0.59
Jasper Therapeutics Inc stock is traded at $21.57, with a volume of 13,301.
It is up +3.86% in the last 24 hours and up +9.50% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
See More
Previous Close:
$20.98
Open:
$21
24h Volume:
13,301
Relative Volume:
0.05
Market Cap:
$314.73M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-21.79
EPS:
-0.99
Net Cash Flow:
$-52.33M
1W Performance:
-1.40%
1M Performance:
+9.50%
6M Performance:
-5.67%
1Y Performance:
+239.94%
1-Day Range:
$20.98
$21.83
1-Week Range:
$19.12
$22.29
52-Week Range:
$4.00
$31.01
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| JSPR | 21.49 | 314.73M | 0 | -64.47M | -52.33M | -0.99 |
| VRTX | 449.15 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.75 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.56 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.60 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.56 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma (NASDAQ:JSPR) - Seeking Alpha
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate - Yahoo Finance
Is Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes mast cell stock - Investing.com
Jasper Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Jasper Therapeutics to Present Briquilimab Updates at Major Healthcare Conferences | JSPR Stock News - StockTitan
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $74.86 - MarketBeat
Stifel Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation - MSN
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) News: Jasper Therapeutics, Inc. Reports Third Quarter 2024 Results - Defense World
Analysts Bullish on Jasper Therapeutics as Briquilimab Trials Show Promise - GuruFocus.com
Jasper Therapeutics Advances in Antibody Therapy Development - TipRanks
Jasper Therapeutics Inc (JSPR) Quarterly 10-Q Report - Quartzy
McDonald's Corp (MCD-N) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail
Nasdaq Other Finance Index (OFIN) QuotePress Release - The Globe and Mail
(JSPR) Long Term Investment Analysis - Stock Traders Daily
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
Net Present Value Model: Jasper Therapeutics Inc’s Briquilimab - GlobalData
JSPRJasper Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Long Term Trading Analysis for (JSPR) - Stock Traders Daily
Jasper Therapeutics' SWOT analysis: briquilimab stock shows promise amid challenges - Investing.com
Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from HC Wainwright - MarketBeat
Jasper Therapeutics to Present Preclinical Briquilimab Data - GlobeNewswire
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - StockTitan
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria - GlobeNewswire
Molina Healthcare (MOH) Set to Announce Earnings on Wednesday - Defense World
Analysts Set Rush Street Interactive, Inc. (NYSE:RSI) Target Price at $11.17 - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $74.86 Consensus Target Price from Brokerages - MarketBeat
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline News & Insights
Jasper Therapeutics (NASDAQ:JSPR) Rating Reiterated by HC Wainwright - Defense World
Metagenomi (NASDAQ:MGX) Stock Rating Reaffirmed by HC Wainwright - Defense World
JMP Securities Reiterates Market Outperform Rating for Jasper Therapeutics (NASDAQ:JSPR) - Defense World
JMP Securities analysts initates a Mkt outperform rating for Jasper Therapeutics Inc (JSPR) - Knox Daily
Analysts review Ares Capital Corp’s rating - Knox Daily
Jasper Therapeutics shares keep buy rating with positive study results By Investing.com - Investing.com Canada
DoubleVerify Holdings Inc [DV] stock was sold by Allais Nicola T at the price of US$30365.0 - Knox Daily
When (JSPR) Moves Investors should Listen - Stock Traders Daily
Jasper Therapeutics Inc (JSPR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Jasper gains 11% on data for briquilimab in urticaria (NASDAQ:JSPR) - Seeking Alpha
Jasper Therapeutics shares hold as Oppenheimer maintains $80 target By Investing.com - Investing.com Canada
Jasper Therapeutics shares hold as BTIG maintains $90 target By Investing.com - Investing.com UK
You Should Read This Analysis Before Investing in Jasper Therapeutics Inc (NASDAQ:JSPR) - US Post News
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? - Yahoo Finance
Jasper reports promising early results in urticaria study - Investing.com
Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday? - Benzinga
Jasper Therapeutics Stock Gains on Strong Briquilimab Trial Results - MarketWatch
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewswire
Jasper reports promising early results in urticaria study By Investing.com - Investing.com UK
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):